[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549064":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":44,"collaborators":11,"id":46,"slug":11,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Shenzhen Geno-Immune Medical Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CAR-T cells to treat MM","EXPERIMENTAL",null,[13],"Biological: CAR-T cells",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","CAR-T cells","Infusion of multi-CAR-T cells",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Lung-Ji Chang, ph.D","CONTACT","+86 0755-86573763","c@szgimi.org",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Shenzhen Geno-immune Medical Institute","RECRUITING","Shenzhen","Guangdong","518000","China","CN",{"type":36,"coordinates":37},"Point",[38,39],114.0683,22.54554,{"lat":39,"lon":38},[42],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":43},"c@szgimi.com",{"type":45,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100549064",false,"NCT06429150","Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma","Frontline Management of High-Risk Multiple Myeloma or Plasmacytoma With BCMA and GPRC5D Combination CAR-T Cell Therapy","Inclusion Criteria:\n\n* Male and female subjects with multiple myeloma or plasmacytoma\n* Strictly complete remission (sCR) is a treatment goal\n* Expected survival \\> 12 weeks\n* After prior auto-SCT is eligible regardless of other prior therapies\n* Adequate venous access for apheresis, and no other contraindications for leukapheresis\n* Voluntary informed consent is given and commitment to continued follow-up\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Uncontrolled active infection\n* Active HIV, hepatitis B or hepatitis C infection\n* Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.\n* Any medical conditions that may preclude participation","ALL","18 Years","80 Years",{"count":56,"type":57},20,"ESTIMATED","INTERVENTIONAL",[60,61],"PHASE1","PHASE2","The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.",[64,65],"Multiple Myeloma","Plasmacytoma",[67,68,69,70],"multiple myeloma","chimeric antigen receptor","BCMA","GPRC5D","2026-06-18",{"date":73,"type":74},"2026-06-23","ACTUAL",{"date":76,"type":74},"2024-05-11",{"date":78,"type":57},"2027-12-31",{"name":5,"class":6},1]